Allspring Global Investments Holdings LLC Sells 115,810 Shares of Natera, Inc. (NASDAQ:NTRA)

Allspring Global Investments Holdings LLC reduced its holdings in Natera, Inc. (NASDAQ:NTRA) by 9.4% in the fourth quarter, HoldingsChannel reports. The firm owned 1,113,748 shares of the medical research company’s stock after selling 115,810 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Natera were worth $178,805,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. Gladstone Institutional Advisory LLC raised its holdings in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock valued at $574,000 after purchasing an additional 61 shares during the period. Guided Capital Wealth Management LLC bought a new stake in Natera in the 4th quarter valued at about $1,788,000. Savant Capital LLC raised its stake in Natera by 1.4% during the 4th quarter. Savant Capital LLC now owns 18,933 shares of the medical research company’s stock worth $2,997,000 after buying an additional 259 shares during the period. Apollon Wealth Management LLC boosted its holdings in Natera by 10.5% in the fourth quarter. Apollon Wealth Management LLC now owns 2,345 shares of the medical research company’s stock worth $371,000 after acquiring an additional 222 shares in the last quarter. Finally, Golden State Wealth Management LLC acquired a new stake in Natera in the fourth quarter valued at approximately $79,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NTRA has been the topic of a number of research reports. Sanford C. Bernstein upped their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Canaccord Genuity Group upped their price objective on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Morgan Stanley raised their price objective on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Guggenheim upped their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Finally, JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 669 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares in the company, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the transaction, the director now owns 19,386 shares of the company’s stock, valued at $3,073,262.58. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 312,394 shares of company stock worth $52,333,520 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Stock Down 1.4 %

NASDAQ NTRA opened at $169.71 on Wednesday. The business’s fifty day moving average is $167.72 and its 200-day moving average is $141.94. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a one year low of $67.33 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. The company’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.